| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
N-Benzylpalmitamide targets fatty acid amide hydrolase (FAAH), the primary enzyme that hydrolyzes endocannabinoids such as anandamide. By inhibiting FAAH, it increases the levels of endogenous cannabinoids, thereby modulating the endocannabinoid system. The compound inhibits FAAH in a time-dependent manner.
|
|---|---|
| ln Vitro |
N-Benzylpalmitamide is an inhibitor of fatty acid amide hydrolase (FAAH). The inhibitory effects on FAAH at doses of 10 μM and 500 μM are 24.8% and 43.8% respectively [1].
In vitro, N-Benzylpalmitamide acts as an inhibitor of fatty acid amide hydrolase (FAAH). The inhibitory effects on FAAH are time-dependent. By inhibiting FAAH, it prevents the breakdown of endocannabinoids, leading to increased concentrations of these signaling molecules. This mechanism is similar to that of other FAAH inhibitors being investigated for pain, inflammation, and neurological disorders. |
| ln Vivo |
In vivo activity data for N-Benzylpalmitamide are limited. As a FAAH inhibitor, it is expected to elevate endocannabinoid levels in vivo, potentially modulating pain perception, inflammation, and mood. Macamides from maca have been traditionally used for their purported aphrodisiac and energizing effects. Further in vivo studies are needed to confirm these activities and establish pharmacokinetic and efficacy profiles.
|
| Enzyme Assay |
In vitro enzyme assays for N-Benzylpalmitamide are conducted to evaluate FAAH inhibition. FAAH activity is measured using a fluorescent substrate such as arachidonoyl-7-amino-4-methylcoumarin amide (AMC). The enzyme hydrolyzes the substrate to release the fluorescent AMC, which is measured at excitation/emission of ~355/460 nm. The compound is incubated with FAAH and substrate at varying concentrations, and IC50 values are calculated from inhibition curves.
|
| Cell Assay |
Cellular assays for N-Benzylpalmitamide are performed using cell lines expressing FAAH. Cells are treated with compound concentrations ranging from 0.1 to 100 µM for 1-24 hours. FAAH activity is measured in cell lysates using fluorescent substrates. Endocannabinoid levels (e.g., anandamide, 2-AG) are quantified by LC-MS/MS to confirm FAAH inhibition. Cell viability is assessed to evaluate cytotoxicity.
|
| Animal Protocol |
In vivo animal studies for N-Benzylpalmitamide would typically utilize rodent models of pain, inflammation, or neurological disorders. The compound is administered orally or intraperitoneally. Endpoints include behavioral assessments (e.g., pain threshold, locomotor activity), tissue endocannabinoid levels, and inflammatory markers. Standard toxicology and PK parameters are also assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of N-Benzylpalmitamide are not well characterized. The compound has a molecular weight of 345.56 and is a lipophilic long-chain fatty acid amide. It is expected to have good membrane permeability and oral absorption. Stability in solution has rarely been reported. Standard PK studies in rodents would be required to determine half-life, bioavailability, and tissue distribution.
|
| Toxicity/Toxicokinetics |
Toxicological data for N-Benzylpalmitamide are limited. As a natural product-derived compound from maca, it is expected to have a favorable safety profile at dietary levels. No significant acute toxicity has been reported. The compound is designated for research use only. Standard toxicity screening would involve acute and repeated-dose studies in rodents.
|
| References | |
| Additional Infomation |
N-Benzylhexadecanoamide is an amide compound formed by the condensation of the carboxyl group of hexadecanoic acid with benzylamine. It is a moderately potent inhibitor of fatty acid amide hydrolases. It has neuroprotective effects, is a plant metabolite, and is also an EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor. It is a secondary amide and amide compound functionally related to hexadecanoic acid and benzylamine. N-Benzylpalmitamide has been reported in Lepidium meyenii, and relevant data are available. See also: Roots (parts) of Lepidium meyenii.
N-Benzylpalmitamide is a macamide isolated from Lepidium meyenii (maca) that inhibits fatty acid amide hydrolase (FAAH) in a time-dependent manner. It is structurally related to cannabinoids and modulates the endocannabinoid system by preventing the breakdown of endocannabinoids. It is not clinically approved and is used as a research tool for studying FAAH inhibition and endocannabinoid signaling. |
| Molecular Formula |
C₂₃H₃₉NO
|
|---|---|
| Molecular Weight |
345.56
|
| Exact Mass |
345.303
|
| CAS # |
74058-71-2
|
| PubChem CID |
11198769
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
95-96℃
|
| LogP |
7.624
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
25
|
| Complexity |
297
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
MLGPKWUKOQAAGI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H39NO/c1-2-3-4-5-6-7-8-9-10-11-12-13-17-20-23(25)24-21-22-18-15-14-16-19-22/h14-16,18-19H,2-13,17,20-21H2,1H3,(H,24,25)
|
| Chemical Name |
N-benzylhexadecanamide
|
| Synonyms |
Macamide 1; N-Benzylhexadecanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~2.5 mg/mL (~7.23 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8939 mL | 14.4693 mL | 28.9385 mL | |
| 5 mM | 0.5788 mL | 2.8939 mL | 5.7877 mL | |
| 10 mM | 0.2894 mL | 1.4469 mL | 2.8939 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
